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Summary Blood pharmacokinetics and tissue distribution of 5-dihydroxyboryl-6-propyl-2-thiouracil (BPTU),
a boron carrier with postulated melanin-seeking properties for boron neutron capture therapy, were deter-
mined in C57/BL mice with subcutaneous pigmented or non-pigmented B16 melanomas. Borocaptate sodium
(BSH) was used as a boron compound without melanin-seeking properties in a comparative biodistribution
study in the same animal tumour models. Administration of single doses showed that BPTU was retained
better in the pigmented B16 tumour than in the non-pigmented variant. BPTU was found in large concentra-
tions in kidney and liver. Brain boron was approximately 10-fold lower than tumour boron. On a molar basis,
BPTU demonstrated higher affinity for B16 tumours than BSH. Owing to solubility limits, tumour boron
concentrations in this mouse study were too low for effective application of BNCT. However, the high
tumour-to-blood and tumour-to-normal tissues ratios indicate that, with appropriate formulation, BPTU
could be a promising candidate for clinical BNCT.
The primary goal of boron neutron capture therapy (BNCT)
at the present time is to achieve more effective treatments for
glioma and melanoma than conventional radiotherapy (Allen
et al., 1989; Slatkin, 1991). The selective accumulation of
"'B-containing compounds in tumours and subsequent
irradiation with low-energy (thermal) neutrons form the basis
of BNCT. The short track lengths of `'B(n,a)7Li fission pro-
ducts (9 and 5iLm for a and 7Li respectively) offer partial
restriction of the radiation dose to the "'B-containing cells.
Additional advantages owing to the high-LET (linear energy
transfer) character of the emitted radiation are higher
biological efficacies compared with photons or X-rays and
less effect of hypoxia or cell cycle distribution on the
therapeutic effect. The relatively high resistance of
melanomas for photon therapy and the presence of a bio-
chemical rationale for boron targeting explain the efforts
made in this area (Mishima et al., 1989; Madoc Jones et al.,
1990). The often high rate of melanogenesis in melanoma
cells has led to the development of several boron drugs with
melanoma-seeking capacity.
The L-isomer of boronphenylalanine (BPA) is taken up by
melanoma cells both in vitro and in vivo (Ichihashi et al.,
1982; 1989; Coderre et al., 1987; 1990; Allen et al., 1992;
Packer et al., 1992). Animal studies on BNCT efficacy and
normal tissue tolerance with BPA have also been performed
(Coderre et al., 1991; 1992; Hiratsuka et al., 1991). Although
the uptake of BPA in melanoma cells is well accepted, incor-
poration of boron into melanin might not occur, resulting in
poor retention. Boronated thiouracils that enter the
melanogenesis pathway at a different point from BPA have
been recently synthesised, aiming at boron incorporation into
the melanin for better retention (Tjarks & Gabel, 1991). We
have found previously that 5-dihydroxyboryl-6-propyl-2-
thiouracil (BPTU) and not boronthiouracil (BTU) was
retained in vitro in melanotic B16 cells, while BPTU failed to
be retained in the non-pigmented B16.013 subclone (R. Verrijk
et al., 1991, unpublished data).
Since the radiation dose in BNCT is mainly dependent on
cellular boron levels, amelanotic tumour cell subpopulations
may limit the efficacy of boron compounds that target the
pigmented tumour cell fraction only. Although pigmented
melanomas do not appear to have a tendency to differentiate
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into cell populations with different pigmentation levels in
experimental tumour models, melanomas often increase in
the amelanotic fraction with tumour progression and metas-
tasis development in humans (Guiliano et al., 1982; Elder,
1987). It is therefore important to establish the capacity of
melanoma-seeking boron drugs to target the amelanotic cells
in a tumour.
We have therefore studied the pharmacokinetics and
biodistribution of BPTU in mice bearing pigmented and
non-pigmented B16 tumours and compared them with BSH
as a reference compound without evident melanoma-seeking
properties. From the experimental data, boron-related
physical radiation doses to tumour and normal tissue were
calculated to compare the efficacy of BPTU and BSH in
melanoma with varying degrees of pigmentation.
Materials and methods
Drugs
Borocaptate sodium (Na2Bl2H,,Sh,BSH) and 5-dihyroxy-
boryl-6-propyl-2-thiouracil (BPTU) were obtained through
the European Concerted Action for BNCT (D. Gabel,
University of Bremen, Germany). BSH was synthesised by
Centronic, Croydon, UK, and BPTU was synthesised by D.
Gabel. Both compounds were 95% enriched in "'B.
Animal models
The well-established melanotic B16 mouse melanoma cell line
(which arose spontaneously in 1954 on the skin at the base of
the ear in a C57/BL/6 mouse) and an amelanotic subline
B16.013 donated by J.A. Coderre (Brookhaven National
Laboratories, Upton, USA) were maintained in Dulbecco's
modified Eagle medium (DMEM) supplemented with 10%
fetal calf serum (Flow Laboratories), 100 IU ml-' penicillin
and 100iLgml-' streptomycin, in an incubator containing
5% carbon dioxide at 37°C. B16 cells were passaged in vitro
for up to 40 passages before being returned to frozen stock.
The RIF-I cell line is a radiation-induced fibrosarcoma and
was maintained by the protocol described by Twentyman et
al. (1980) involving alternating in vitro and in vivo passaging
and no more than three in vivo passages before being
returned to the frozen stock. Cells were harvested by tryp-
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sinisation with 0.05% (w/v) trypsin in phosphate-buffered
saline (PBS, 0.01 M, pH 7.4) and washed one with PBS.
Tumours were initiated on the lower back by subcutaneously
injecting 5 x I05 cells in 0.1 ml into syngeneic C57/BL and
C3H/Km mice for B16 and RIF-1 tumours respectively. Four
weeks later palpable tumours were present in at least 90% of
the inoculated animals and pharmcokinetic and biodistribu-
tion experiments were started. Animals bearing the same
tumour type were randomly assigned to treatment groups.
The average tumour diameter was approximately 8 mm.
Drug formulations were freshly prepared prior to adminis-
tration. BSH was dissolved in saline and injected at a dose of
50mgkg-' boron via a tail vein. BPTU was dissolved in
0.1 M sodium hydroxide at a concentration of 11.2 mg ml
and diluted with water to a final concentration of 6.75
mg ml-' and a pH not exceeding 8. Mice were given BPTU
intraperitoneally at doses of 3.15 mg of boron per kg body
weight. Injection volumes ranged from 0.25 to 0.5 ml for
both intravenous and intraperitoneal administrations. Six
mice were not given any drug to allow measurement of boron
background levels.
Animals were killed with carbon dioxide 0.2, 0.4, 1, 2, 4,
24 and 48 h after drug administration and samples were
taken from tumour, blood, skin, muscle, brain, kidneys and
liver. Tumour tissue from mice bearing B16.013 tumours was
checked by eye for the absence of pigmentation. No reversal
of pigmentation grade was encountered during the study. For
each time point 6-8 animals were used.
BPTU was also given in a multiple dose scheme. Every 2 h
0.4-0.5 ml of the above-mentioned BPTU solution was given
intraperitoneally (4 x 3.15 mg kg-' boron). Twenty-four hours
after the last administration, the animals were sacrificed and
samples were taken.
Boron analysis
Boron was measured by inductively coupled plasma atomic
emission spectroscopy (ICP-AES) after acid digestion of tis-
sue. In brief, samples were weighed (<0.5 g) and mixed
with 1.5 ml of an acidic mixture consisting of 4% (v/v)
perchloric acid (68%) in nitric acid (65%). Samples were
spiked with a 0.5 ml of 40.00 lag g-' cobalt (nitrate) as inter-
nal standard. Digestion was done in a CEM-2000 microwave
oven operated at full power for 30 min with a pressure limit
of 80 p.s.i. Liver and blood samples were processed with a
milder regimen of 50% power for 50 min and a pressure limit
of 50 p.s.i. After digestion 0.5 ml of a 40.00 tg g-' yttrium
solution (nitrate) was added to allow for compensation of
possible drift of the ICP machine. Finally, 3 ml of water and
0.5 ml of a 4% (v/v) solution of hydrogen fluoride (38%)
were added to avoid a 'memory effect' of boron in the ICP
machine tubing. ICP measurement were done with a Jobin
Yvon JY70 Plus. The detection limit of the ICP-AES was
established to be approximately 0.01 gg g-' boron. Back-
ground levels of boron in untreated tumour-bearing mice
were negligible.
Theoretical radiation dose calculation
Boron-related physical radiation dose rates were calculated
with a three-dimensional microdosimetry PC-based computer
programm, previously described by us (Verrijk et al.,
1994). Briefly, energy deposition of boron neutron capture
products, alpha particles and lithium ions were cumulatively
recorded in a spherical nucleus modelled in a cuboidal cell.
Capture reactions were simulated to occur randomly in this
cell or in the surrounding cell layer. Analogous to tissue with
two tumour cell populations having different boron uptake
and retention properties, a situation could be simulated in
which the effect of charged particle 'cross-fire' between cells
could be studied. Assumptions were made that pigmented
and non-pigmented cells have equal geometrical dimensions
and that no boron was present in either cell nuclei. Equal
boron concentrations were assumed in cytoplasm and tissue
interstitium. For this particular example, cells with an
average volume of 1,000fLm3 were chosen. Dose rates are not
corrected for relative biological effectiveness (RBE).
A thermal neutron flux of 5.45 x I09 n cm-2 s'- was used
in the calculation, taken from publications on BNCT
experiments at the Brookhaven Medical Research Reactor
(BMRR) in Upton, USA (Gabel et al., 1984). Other radia-
tion components from the neutron beam or generated by
other capture events were disregarded, since they are not
influenced by boron uptake or retention in cells.
Data analysis
Boron concentrations are expressed as mean ± standard error
of mean (s.e.m.). Radiation doses are given without correc-
tion for RBEs. Blood pharmacokinetics were analysed by
weighted non-linear curve fitting using a two-compartment
model with first-order absorption where appropriate. Non-
linear optimisation was done with a simplex routine. Errors
on curve fit parameters are standard deviations. Statistical
analyses of estimated pharmacokinetic parameters were done
with non-parametric Mann-Whitney tests. P<0.05 was con-
sidered significant.
Results
Uptake of BPTU from the peritoneal cavity was relatively
rapid. Blood boron levels were maximal within 1 h after
administration. Figures 1 and 2 show pharmacokinetic
profiles of boron in blood, tumour, muscle, brain and skin in
pigmented and non-pigmented melanoma-bearing mice in-
jected with BPTU or BSH, over a time span of 48 h. After
only 1 h, a boron tumour-to-blood ratio above 1 was found
for BPTU in pigmented tumours, which is indicative of drug
retention. This was not seen in the non-pigmented tumour
variant, in which tumour boron levels closely followed blood
levels. Up to 24 h, BSH exhibited no selective retention in
either tumour, but achieved higher maximum tumour boron
concentrations than BPTU as a result of the administration
of higher amounts of boron. At 24 and 48 h, boron levels
were significantly higher than in blood, although the mean
tumour boron concentration had decreased considerably. At
times before 24 h boron tumour-to-blood ratios were always
below 1, and tumour concentrations were generally lower
than in the B16 tumours. Similar results have been reported
previously (Gregoire et al., 1993). To investigate whether this
was dependent on the tumour type, we repeated the BSH
pharmacokinetic experiment in C3H/Km mice with the sub-
cutaneous fibrosarcoma RIF-1. In this tumour model no
significantly different tumour and blood boron levels were
observed at 24 or 48 h after administration (Figure 3).
Brain and muscle boron concentrations were always
significantly lower than tumour levels for both drugs
throughout the measured 48 h in all three tumour models.
Skin boron levels were similar to those in blood for both
boron compounds. Liver and kidney boron concentrations
were mostly above tumour values, especially during the tissue
distribution (alpha) phase, irrespective of drug and tumour
model (Figure 4). Pharmacokinetics in these organs was not
dependent on tumour type carried by the host. BSH
accumulated extensively in liver; boron levels up to
230Agg- g were found 12 min after administration, which
were 8-fold higher than in blood. During the tissue distribu-
tion phase, liver-to-kidney boron concentration ratios ranged
from 2 to 4 for BSH and from 0.5 to 1 for BPTU. This may
be indicative of the roles of liver and kidneys in the elimina-
tion of these two drugs.
A summary of values for elimination of boron from blood
is given in Table I. Parameters were analysed with an open
two-compartment model. A first-order absorption parameter
was added for BPTU to account for peritoneal resorption.
As expected, no significant differences were found between
animals bearing the pigmented and the non-pigmented
tumours. The elimination half-lives ranged from 1.5 to 3 h.
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than BSH. Volumes of distribution were not significantly
different. Owing to the higher administered boron dose, BSH
had approximately 10-fold higher C. values than BPTU.
Table I also shows that the uptake and retention properties
of BPTU, after correction for the administered dose (mean
ratio CtUlnfUr/injected dose), are better in pigmented B16
tumours, and also better than those for BSH in B16 tumours,
whether pigmented or not. Table II summarises boron
tumour-to-blood ratios of BPTU and BSH in pigmented and
non-pigmented B16 melanomas at 4 and 24h after single
administrations. Since the mean tumour boron concentration
is an important parameter in BNCT, it is also listed. The
calculated boron-related radiation dose rates to completely
pigmented or non-pigmented tumours are given in the last
column. As expected, large differences between tumour types
existed for BPTU, while the calculated efficacy for BSH was
not influenced by the absence of pigmentation. Although
tumour boron levels were higher for BSH at times before 4 h,
they were not accompanied by favourable tumour-to-blood
ratios. Solubility limitations of BPTU prevented us from
giving higher single doses. Therefore, to increase the absolute
tumour boron levels, we investigated the effect of multiple
dosing on the tissue distribution of boron in mice with
pigmented B16 tumours at 24 h after four intraperitoneal
injections with BPTU (4 x 3.15 mg kg-' boron). Boron
values (in jig g-') were 3.7 ± 1.1 for tumour, 0.13 ± 0.07 for
blood, 0.3 ± 0.3 for brain, 0.58 ± 0.2 for skin, 0.27 + 0.1 for
muscle, 0.4 ± 0.1 for liver and 0.7 ± 0.5 for kidney. Com-
pared with the single BPTU administration, the mean
tumour boron concentration increased more than three times
and the tumour-to-blood ratio increased 1.8 times, indicating
increased retention of boron in the tumour vs normal tissue.
Discussion
The present study shows that BPTU has melanoma-seeking
properties in an in vivo tumour model system. A higher
retention in pigmented tumours is indicative of the pos-
tulated mechanism of uptake of thiouracil derivatives via the
melanogenesis pathway. Boronophenylalanine (BPA) was one
of the first compounds aimed at a biochemical mechanism
and showed active uptake in melanomas in vivo (Coderre et
al., 1987; Mishima et al., 1989). It was demonstrated, how-
ever, that the mechanism of BPA uptake is not unique for
melanomas (Coderre et al., 1990). Melanoma-selective
boronated thiouracils were synthesised by Tjarks and Gabel
(1991) with the presumption that these compounds will be
incorporated into melanin, giving long boron retention in
melanoma cells, analogous to non-boronated thiouracils
(Fairchild et al., 1982; Yamada et al., 1988; Tjarks & Gabel,
1991). Of these drugs, we have previously investigated BTU
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Figure 4 Boron concentrations in liver (top) and kidneys (bot-
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boron) or BSH (50mgkg-' boron) in B16 wt, B16.013 (C57/BL
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and BPTU in vitro. After washing, it was observed that
BPTU was better retained in the cells than BPA or BSH.
BPTU was not retained in non-pigmented B16 cells and BTU
showed no retention at all in either cell line.
The pigmented and non-pigmented B16 melanoma tumour
models used here showed large differences in tumour reten-
tion of BPTU, despite equal boron pharmacokinetics in
blood, indicating that a lower pigmentation degree limits the
tumour boron concentration. Since initial tumour boron con-
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Figure 5 Amelanotic cell fraction in a partially pigmented
melanoma vs calculated boron-related radiation dose rate (in.
arbitrary units) to pigmented cells (0), non-pigmented cells (-),
and the entire tumour (- - -). The left panel shows a tumour 4 h
after a single dose of BPTU (3.15 mg kg-' boron); the right panel
24 h after a single BPTU dose (3.15 mg kg-' boron).
centrations and pharmacokinetics in other tissues and in
blood were the same in both pigmented and non-pigmented
melanomas, we conclude that the retention capacity is higher
in the pigmented tumour type. Tumour vasculature also
influences tumour distribution, but differences in blood sup-
ply would have been reflected by an increase in initial tumour
boron uptake, which was not found. A better tumour vas-
culature supply would also result in an improved elimination
of boron from the tumour tissue. No differences in tumour
pharmacokinetics were found after administration of BSH, a
BNCT compound without apparent melanoma-seeking pro-
perties. Nevertheless, BSH was retained in B16 tumours at 24
and 48 h, irrespective of pigmentation degree. In contrast,
tumour-to-blood ratios of BSH in mice carrying sub-
cutaneous RIF-I fibrosarcomas were not significantly above
unity, implying that the observed retention in B16 tumours is
not a property common to all types of tumours. Our own in
vitro studies have shown that levels of boron in melanotic
B16 cells were higher than in the culture medium only after
16 h incubation with BSH (Verrijk et al., 1992). Partial cel-
lular boron retention was also found after washing the cells
with boron-free culture medium for 4 h. It was speculated
that this may have been caused by the handling of
sulphydryl-containing compounds in the melanin biochemical
pathway present in melanoma cells (Jara et al., 1988). If this
is valid for BSH, the present studies would support the
theory that the BSH retention mechanism is not as closely
linked to expression of melanogenesis in B16 cells as the
mechanism that retains BPTU.
If BNCT is applied for glioma treatment, the boron con-
centration in blood is a primary factor that determines the
dose to capillary endothelial cells, which is considered to be
the dose-limiting tissue for brain. In addition, low brain
boron levels will help to reduce the high LET radiation dose
to endothelial cells by geometrical sparing (Wheeler et al.,
1989). Boron found in brain tissue was lower than in blood
and other tissues in all pharmacokinetic studies presented in
Table I Pharmacokinetic parameters ofBPTU and BSH in B16melanoma-bearing C57/BL
mice
BPTUI
BPTU/BJ6wt B16.013 BSH/BJ6wt BSH/B16.013
Dose (mg kg-') 3.15 3.15 50 50
K"'r (h') 0.39 + 0.03 0.39 ± 0.12 0.33 ± 0.13 0.26 ± 0.43
tblood (h) 1.77 0.12 1.77±0.52 2.11 0.84 2.68 4.4
Vd (ml g' 0.64 ± 0.04 0.57 ± 0.09 0.84 ± 0.15 0.92 ± 0.25
body weight)
Cmax g mli)a 4.90 ± 0.35 5.48 0.82 59.4 + 10.6 54.1 + 14.6
C'max (g mg-)b 11.89 3.12 6.97 1.17 32.8 3.52 49.8 11.0
Mean ratio Ctu'Our/ 3.8 2.2 0.7 1.0
injected dose
Correlation of the fit 0.996 0.981 0.989 0.986
K,,, elimination constant; t,/21,, elimination half-life; Vd, volume of distribution; Cmax,
maximum boron concentration in blood or tissue. Values refer to boron. BPTU was
administered intraperitoneally, BSH intravenously. aCalculated values. bHighest measured
values.
Table II Biodistribution results summary
Tumour
Boron dose Tumour Tumour-to- boron conc.
Compound (mgkg-') Time (h) type blood ratio (gg-g')
BPTU 3.15 4 B16.wt 6.1 3.8
B16.013 1.7 0.6
24 B16.wt 18.7 1.1
B16.013 1.3 0.08
BSH 50 4 B16.wt 1.1 7.6
B16.013 1.5 10.5
24 B16.wt 3.4 2.3
B16.013 4.0 2.2
BPTU 4 x 3.15 24 B16.wt 35 3.7646 R. VERRIJK et al.
this paper. Although the blood-brain barrier is presumably
an important factor that determines the amount of boron
found in brain tissue, exclusion of boron compounds from
the cell interior will also influence macroscopic boron levels.
Since brain tissue has a very small interstitial space compared
with other tissues, low brain boron levels may also be caused
by an ability to penetrate the blood-brain barrier combined
with a limitation to cross the cell membrane. A review of
human and animal data on extracellular spaces in tumour
and normal tissues has been made by Jain (1987). Strikingly,
relative tissue boron levels from BSH in tumour-bearing mice
are consistent with the relative extracellular volumes reported
for tumour, skin, muscle and brain tissue. However, assum-
ing that BSH is mainly located extracellularly in vivo would
be speculative, since microdistribution of BSH in vivo is still
unknown, despite efforts being made to resolve this question
(Zha et al., 1992). In addition, binding of BSH to plasma and
tissue proteins can influence cellular uptake and retention
(Bauer et al., 1992). BPTU retention appears to be highly
dependent on pigmentation level, and we have therefore cal-
culated the effect of varying fractions of non-pigmented cells
in a tumour since these could limit cure. In Figure 5 the
fraction of non-pigmented cells in a B16 melanoma is plotted
against the calculated boron-related dose rate to pigmented
cells, non-pigmented cells and to the entire tumour. The
relatively small effect of 'cross-fire' (dose from a capture
reaction in a neighbouring cell) is well illustrated here; radia-
tion dose rates to both tumour cell types decline with increas-
ing non-pigmented fraction. The dose rate to the entire
tumour starts to decrease significantly at amelanotic fractions
above 10%, up to a more than 8-fold dose rate reduction
for a completely non-pigmented tumour. Since there is no
difference in accumulation of BSH in pigmented and non-
pigmented tumour cells, amelanotic tumour cell subpopula-
tions do not influence the radiation dose to the tumour.
It is realised that the BPTU dose administered to mice was
limited by insufficient solubility of the compound. We chose
not to investigate methods to improve the formulation, but
chose instead to use this relatively low dose in a model study.
In larger animals, or in humans, formulation problems of
this kind can probably be more easily overcome.
We conclude that BPTU is selectively accumulated and
retained in a pigmented experimental melanoma model. The
non-pigmented variant shows significantly less boron reten-
tion. If boron compounds targeted to melanogenetic activity
such as BPTU are used, melanomas with a significant non-
pigmented tumour cell fraction will receive less radiation
dose than fully pigmented tumours. This will depend on the
degree ofmelanogenetic activity on a cell-by-cell basis and on
the dispersion pattern of amelanotic cells in the tumour.
Clustered amelanotic cells will receive less radiation than
single amelanotic cells because of the influence of 'cross-fire'
between pigmented and non-pigmented cells. Amelanotic
cells are then the most likely survivors after BNCT employ-
ing BPTU. It appears that so-called non-specific boron com-
pounds such as BSH would be more favourable in these
situations. It should be noted, however, that retention pro-
perties of BPTU in amelanotic B16 tumours are not worse
than those of BSH in B16 tumours and that the total radia-
tion dose rate may be increased by using higher doses of
BPTU. Using repeated adminsitrations of this compound and
a well-chosen irradiation interval may lead to effective BNCT
for inoperable superficial melanomas or for cerebral
melanoma metastases.
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